TY - JOUR T1 - A common allele of HLA mediates asymptomatic SARS-CoV-2 infection JF - medRxiv DO - 10.1101/2021.05.13.21257065 SP - 2021.05.13.21257065 AU - Danillo G. Augusto AU - Tasneem Yusufali AU - Joseph J. Sabatino, Jr. AU - Noah D. Peyser AU - Lawton D. Murdolo AU - Xochitl Butcher AU - Victoria Murray AU - Vivian Pae AU - Sannidhi Sarvadhavabhatla AU - Fiona Beltran AU - Gurjot Gill AU - Kara Lynch AU - Cassandra Yun AU - Colin Maguire AU - Michael J. Peluso AU - Rebecca Hoh AU - Timothy J. Henrich AU - Steven G. Deeks AU - Michelle Davidson AU - Scott Lu AU - Sarah A. Goldberg AU - J. Daniel Kelly AU - Jeffrey N. Martin AU - Cynthia A. Viera-Green AU - Stephen R. Spellman AU - David J. Langton AU - Sulggi Lee AU - Gregory M. Marcus AU - Jeffrey E. Olgin AU - Mark J. Pletcher AU - Stephanie Gras AU - Martin Maiers AU - Jill A. Hollenbach Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/10/12/2021.05.13.21257065.abstract N2 - Despite some inconsistent reporting of symptoms, studies have demonstrated that at least 20% of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will remain asymptomatic. Although most global efforts have focused on understanding factors underlying severe illness in COVID-19 (coronavirus disease of 2019), the examination of asymptomatic infection provides a unique opportunity to consider early disease and immunologic features promoting rapid viral clearance. Owing to its critical role in the immune response, we postulated that variation in the human leukocyte antigen (HLA) loci may underly processes mediating asymptomatic infection. We enrolled 29,947 individuals registered in the National Marrow Donor Program for whom high-resolution HLA genotyping data were available in the UCSF Citizen Science smartphone-based study designed to track COVID-19 symptoms and outcomes. Our discovery cohort (n=1428) was comprised of unvaccinated, self-identified subjects who reported a positive test result for SARS-CoV-2. We tested for association of five HLA loci (HLA-A, -B, -C, -DRB1, -DQB1) with disease course and identified a strong association of HLA-B*15:01 with asymptomatic infection, and reproduced this association in two independent cohorts. Suggesting that this genetic association is due to pre-existing T-cell immunity, we show that T cells from pre-pandemic individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells displayed memory phenotype. Finally, we characterize the protein structure of HLA-B*15:01-peptide complexes, demonstrating that the NQKLIANQF peptide from SARS-CoV-2, and the highly homologous NQKLIANAF from seasonal coronaviruses OC43-CoV and HKU1-CoV, share similar ability to be stabilized and presented by HLA-B*15:01, providing the molecular basis for T-cell cross-reactivity and HLA-B*15:01-mediated pre-existing immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by grants R01AI159260 and 3U2CEB021881-05S1 from the National Institutes of Health, and the National Health and Medical Research Council (NHMRC) and Medical Research Future Fund (MRFF), NHMRC SRF (#1159272). The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); HHSH250201700006C from the Health Resources and Services Administration (HRSA); and N00014-20-1-2832 and N00014-21-1-2954 from the Office of Naval Research; Support is also provided by Be the Match Foundation, the Medical College of Wisconsin and the National Marrow Donor Program. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in accordance with the ethical standards of the UCSF Human Research Protection Program Institutional Review under approvals IRB# 17-21879, IRB# 20-30850, IRB# 20-30588, and IRB# 20-30479, and informed consent was obtained from all individual participants involved in the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is provided in the manuscript and supplementary data ER -